Qualigen Therapeutics (QLGN) 10-K2018 FY Annual report

Filed: 1 Apr 19, 6:21am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: absent, accredited, acknowledge, Australian, Beck, blinded, breakdown, Bulletin, Cadence, capture, complementary, condensed, convention, custodial, customary, eth, Evelo, expedient, gender, goodwill, half, hindsight, Indian, insignificant, Ireland, Israel, John, Korea, Korean, legacy, liver, loosen, mildly, mixture, outdated, paradigm, payroll, PIPE, precise, preferentially, proven, quantitative, reassessed, reclassification, redundant, ROU, SAB, seeNote, Simplification, stranded, Switzerland, Synlogic, Synthetic, text, therapy

Removed: advancing, advice, affiliate, aimed, assigned, benign, chain, clinic, consultant, consummation, Covance, created, debilitating, differentiate, disposal, distinct, earn, edition, elevation, encouraged, Enterome, entitle, equaled, exempt, exerting, expired, favor, fed, Floor, formation, founder, Fundraising, gather, gathered, generation, Genome, guide, incremental, initiate, lapsing, letter, lived, metabolizing, microbiota, milestone, modulator, multiplied, nonrecurring, nonstatutory, noted, nutrient, observational, occurrence, percent, ppm, prevailing, randomization, ratably, relying, renew, replaced, represent, repurchase, retention, SA, salary, short, society, spent, studied, successive, suggesting, sum, technical, therapeutically, thereunder, Thirty, tolerant, toothier, translating, tuition, underwent, unpaid, Vedanta, vice, York

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

QLGN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

As independent registered public accountants, we hereby consent to the incorporation by reference in Registration Statement Nos. 333-213087 and 333-228501 on Form S-3 and Registration Statement Nos. 333-212062, 333-207709, 333-218636, and 333-220907 on Form S-8 pertaining to the 2008 Stock Plan, 2009 Stock Plan, and 2015 Equity Incentive Plan of Ritter Pharmaceuticals, Inc. of our report dated March 29, 2019, with respect to the financial statements of Ritter Pharmaceuticals, Inc. (which report includes an explanatory paragraph relating to the uncertainty of the Company’s ability to continue as a going concern) for each of the years in the two year period ended December 31, 2018, included in this annual report on Form 10-K of Ritter Pharmaceuticals, Inc. for the year ended December 31, 2018.

/s/ Mayer Hoffman McCann P.C.

Orange County, California
March 29, 2019